▲ +61.76% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Aerpio Pharmaceuticals in the last 3 months. The average price target is $2.75, with a high forecast of $4.00 and a low forecast of $1.50. The average price target represents a 61.76% upside from the last price of $1.70.
The current consensus among 2 contributing investment analysts is to buy stock in Aerpio Pharmaceuticals. This rating has held steady since December 2020, when it changed from a Hold consensus rating.
Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing compounds for the treatment of ocular diseases and diabetic complications. The company's lead product candidate is razuprotafib, a small molecule activator of the Tie2 pathway, which completed the Phase IIb clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, which is in a Phase 1b clinical trial for the treatment of inflammatory bowel disease; and bispecific antibody for the treatment for wet age-related macular degeneration and DME through intravitreal injection. Aerpio Pharmaceuticals, Inc. has a collaboration with Quantum Leap Healthcare Collaborative for the evaluation of razuprotafib in the treatment of acute respiratory distress syndrome in adult patients with moderate to severe COVID-19. The company is headquartered in Cincinnati, Ohio.